SS-31 30mg 99% Purity, High Quality White Powder 10mg 15mg 20mg 30mg 50mg Anti fatigue, improve physical fitness Peptide
TDS 26 Inquiries
67727-97-3
Pharmaceutical Grade
99.6%
HK
XINHONG
80mg*10vials
2026-10-09
Retatrutide,Tirzepatide,Semaglutide,GHK-CU,NAD+,MOTS-C
-
Product Description
-
Seller Information
-
Inquiry History
-
DescriptionECHEMI Editorial ReferenceLys-Pro-Val is an oligopeptide.CertificatesBasic Info
-
Product Name:
ALPHA-MSH (11-13) ACETATE SALT
Other Name:H-LYS-PRO-VAL-OH ACETATE SALT;H-LYS-PRO-VAL-OH ACOH;ALPHA-MSH (11-13);ALPHA-MSH (11-13) ACETATE SALT;msh(11-13;.alpha.-MSH (11-13) (free acid);H-Lys-Pro-Val-OH;alpha-Msh (11-13) (free acid) acetate salt
CAS No.:67727-97-3
Molecular Formula:C18H34N4O6
InChIKeys:YSPZCHGIWAQVKQ-AVGNSLFASA-N
Molecular Weight:402.49
Exact Mass:342.226705
Categories:
Characteristics-
PSA:
139
Storage Conditions:-15°C
Research-
Class:
Mitochondria-targeted tetrapeptide (Szeto-Schiller peptide)
Status:FDA-approved (Forzinity) — Accelerated Approval 2025
Mechanism:A cell-permeable, synthetic tetrapeptide (D-Arg-Dmt-Lys-Phe-NH₂) that selectively concentrates in the inner mitochondrial membrane and reversibly binds to cardiolipin, a phospholipid essential for electron transport chain (ETC) function. By stabilizing cardiolipin, SS-31 restores mitochondrial bioenergetics, reduces cytochrome c peroxidase activity, and prevents oxidative damage in cells with impaired mitochondrial function.
Activity note:SS-31 does not act via traditional receptor agonism. It binds cardiolipin with high selectivity in the inner mitochondrial membrane. Functional EC₅₀ values are context-dependent (cell type, stress model). Key electrophysiology studies report mitochondrial membrane potential restoration at nanomolar concentrations.
Source:Szeto HH, et al. AAPS J. 2006;8(2):E277-E283. Birk AV, et al. J Am Soc Nephrol. 2014;25(6):1157-1169.DOI
Clinical Development:FDA:Forzinity (approved 2025-09-19)
References-
ChEMBL:DrugBank:KEGG DRUG:PubChem:Literature:
FDA: Forzinity (NDA 215244) — Accelerated Approval 2025; Genetics in Medicine: TAZPOWER Phase 2/3 results (Thompson et al. 2020); Drugs: Elamipretide First Approval (Springer 2025)
Disclaimer:Elamipretide (Forzinity) is FDA-approved under accelerated approval for Barth syndrome. This listing is for industrial and laboratory research use only. Research-chemical listings on B2B marketplaces are not interchangeable with approved medicines. Confirm CAS, specification, and regulatory pathway with the seller. It is not medical advice, a clinical recommendation, or an approved therapy description.
Hazard IdentificationClassification of the substance or mixture
no data available
GHS label elements, including precautionary statements
Pictogram(s) no data available Signal word no data available
Hazard statement(s) no data available
Precautionary statement(s) Prevention no data available
Response no data available
Storage no data available
Disposal no data available
Other hazards which do not result in classification
no data available
Handling and StoragePrecautions for safe handling
Handling in a well ventilated place. Wear suitable protective clothing. Avoid contact with skin and eyes. Avoid formation of dust and aerosols. Use non-sparking tools. Prevent fire caused by electrostatic discharge steam.
Conditions for safe storage, including any incompatibilities
Store the container tightly closed in a dry, cool and well-ventilated place. Store apart from foodstuff containers or incompatible materials.
-
-
Seller Information
-
Business Type:
Trader
-
Main Products:
Retatrutide,Tirzepatide,Semaglutide,GHK-CU,NAD+,MOTS-C
-
Location:
Block 1, No. 205, Tongbao Road, Jiangdong Street, Yiwu City, Jinhua City, Zhejiang Province (within Zhejiang Juzhiyun Holding Co., Ltd., on the 4th floor of 2 buildings)
-
Payment Terms:
TT against copy of documents,O/A,100% TT in advance
-
Total Employees:
101-200
-
Year of Establishment:
2026
-
-
Inquiry History26 Inquiries
Country Product Purchase Quantity Date Posted 
Brazil
67727-97-3
10 MT Apr 30, 2026 
United States
Klow blends 80mg 10 vials
10 MG Feb 12, 2026
United States
KPV
0.1 G Jul 13, 2026 
Canada
Kpv
10 G May 9, 2026
United States
kpv
1 KG May 8, 2026
Canada
KPV | US Warehouse | Cosmetic Peptides | 99% Purity | 5mg 10mg Vials | Lyophilized Powder
10 MG Apr 16, 2026
United States
KLOW
1 MT Apr 15, 2026
Brazil
kpv
10 MT Mar 12, 2026
United States
KPV
10 MG Feb 28, 2026
United States
Klow80
10 MT Jul 29, 2026
United States
Klow80
1 MT May 23, 2026
Canada
KPV
1 KG Nov 24, 2025
United States
KPV
50 MG Nov 10, 2025
United States
KlOW
20 Aug 9, 2026 
Netherlands
klow
10 MT Jul 9, 2026
United States
Klow
800 MG Jul 3, 2026
United States
KPV
2 KG Jun 19, 2026 
Portugal
KLOW
80 MG May 28, 2026
United States
KPV (KLOW)
100 MT May 18, 2026
United States
Glow blend
10 MT Apr 4, 2026 Post an enquiry for this product
